|
1
|
Johnson DE, Burtness B, Leemans CR, Lui
VWY, Bauman JE and Grandis JR: Head and neck squamous cell
carcinoma. Nat Rev Dis Primers. 6:922020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chow LQM: Head and neck cancer. N Engl J
Med. 382:60–72. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Martincorena I, Raine KM, Gerstung M,
Dawson KJ, Haase K, Van Loo P, Davies H, Stratton MR and Campbell
PJ: Universal patterns of selection in cancer and somatic tissues.
Cell. 171:1029–1041.e21. 2017. View Article : Google Scholar
|
|
4
|
Jhunjhunwala S, Hammer C and Delamarre L:
Antigen presentation in cancer: Insights into tumour immunogenicity
and immune evasion. Nat Rev Cancer. 21:298–312. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Leone P, Shin EC, Perosa F, Vacca A,
Dammacco F and Racanelli V: MHC class I antigen processing and
presenting machinery: Organization, function, and defects in tumor
cells. J Natl Cancer Inst. 105:1172–1187. 2013. View Article : Google Scholar
|
|
6
|
Dhatchinamoorthy K, Colbert JD and Rock
KL: Cancer immune evasion through loss of MHC class I antigen
presentation. Front Immunol. 12:6365682021. View Article : Google Scholar
|
|
7
|
Cai L, Michelakos T, Yamada T, Fan S, Wang
X, Schwab JH, Ferrone CR and Ferrone S: Defective HLA class I
antigen processing machinery in cancer. Cancer Immunol Immunother.
67:999–1009. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mantel I, Sadiq BA and Blander JM:
Spotlight on TAP and its vital role in antigen presentation and
cross-presentation. Mol Immunol. 142:105–119. 2022. View Article : Google Scholar
|
|
9
|
Johnsen AK, Templeton DJ, Sy M and Harding
CV: Deficiency of transporter for antigen presentation (TAP) in
tumor cells allows evasion of immune surveillance and increases
tumorigenesis. J Immunol. 163:4224–4231. 1999.
|
|
10
|
Feenstra M, Veltkamp M, van Kuik J,
Wiertsema S, Slootweg P, van den Tweel J, de Weger R and Tilanus M:
HLA class I expression and chromosomal deletions at 6p and 15q in
head and neck squamous cell carcinomas. Tissue Antigens.
54:235–245. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Meissner M, Reichert TE, Kunkel M, Gooding
W, Whiteside TL, Ferrone S and Seliger B: Defects in the human
leukocyte antigen class I antigen processing machinery in head and
neck squamous cell carcinoma: Association with clinical outcome.
Clin Cancer Res. 11:2552–2560. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bandoh N, Ogino T, Katayama A, Takahara M,
Katada A, Hayashi T and Harabuchi Y: HLA class I antigen and
transporter associated with antigen processing downregulation in
metastatic lesions of head and neck squamous cell carcinoma as a
marker of poor prognosis. Oncol Rep. 23:933–939. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ogino T, Shigyo H, Ishii H, Katayama A,
Miyokawa N, Harabuchi Y and Ferrone S: HLA class I antigen
down-regulation in primary laryngeal squamous cell carcinoma
lesions as a poor prognostic marker. Cancer Res. 66:9281–9289.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ferris RL, Hunt JL and Ferrone S: Human
leukocyte antigen (HLA) class I defects in head and neck cancer:
Molecular mechanisms and clinical significance. Immunol Res.
33:113–133. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Attaran N, Gu X, Coates PJ, Fåhraeus R,
Boldrup L, Wilms T, Wang L, Sgaramella N, Zborayova K and Nylander
K: Downregulation of TAP1 in tumor-free tongue contralateral to
squamous cell carcinoma of the oral tongue, an indicator of better
survival. Int J Mol Sci. 21:62202020. View Article : Google Scholar
|
|
16
|
Taylor BC and Balko JM: Mechanisms of
MHC-I downregulation and role in immunotherapy response. Front
Immunol. 13:8448662022. View Article : Google Scholar
|
|
17
|
Waldman AD, Fritz JM and Lenardo MJ: A
guide to cancer immunotherapy: From T cell basic science to
clinical practice. Nat Rev Immunol. 20:651–668. 2020. View Article : Google Scholar
|
|
18
|
Detre S, Saclani Jotti G and Dowsett M: A
‘quickscore’ method for immunohistochemical semiquantitation:
Validation for oestrogen receptor in breast carcinomas. J Clin
Pathol. 48:876–878. 1995. View Article : Google Scholar
|
|
19
|
Brandwein-Gensler M, Teixeira MS, Lewis
CM, Lee B, Rolnitzky L, Hille JJ, Genden E, Urken ML and Wang BY:
Oral squamous cell carcinoma: Histologic risk assessment, but not
margin status, is strongly predictive of local disease-free and
overall survival. Am J Surg Pathol. 29:167–178. 2005. View Article : Google Scholar
|
|
20
|
Garrido F, Cabrera T, Accolla RS, Bensa
JC, Bodmer W, Dohr G, Drouet M, Fauchet R, Ferrara GB, Ferrone S,
et al: HLA and cancer: 12th international histocompatibility
workshop study. Hla-genetic diversity of Hla functional and medical
implication, proceedings of the twelfth international
histocompatibility workshop and conference (12th Ihwc). Vol.
I:Workshop. 445–452. 1997.
|
|
21
|
Boldrup L, Coates PJ, Laurell G and
Nylander K: Differences in p63 expression in SCCHN tumours of
different sub-sites within the oral cavity. Oral Oncol. 47:861–865.
2011. View Article : Google Scholar
|
|
22
|
Frohwitter G, Buerger H, Korsching E, van
Diest PJ, Kleinheinz J and Fillies T: Site-specific gene expression
patterns in oral cancer. Head Face Med. 13:62017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Montesion M, Murugesan K, Jin DX, Sharaf
R, Sanchez N, Guria A, Minker M, Li G, Fisher V, Sokol ES, et al:
Somatic HLA class I loss is a widespread mechanism of immune
evasion which refines the use of tumor mutational burden as a
biomarker of checkpoint inhibitor response. Cancer Discov.
11:282–292. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Garrido MA, Perea F, Vilchez JR, Rodriguez
T, Anderson P, Garrido F, Ruiz-Cabello F and Aptsiauri N: Copy
neutral LOH affecting the entire chromosome 6 is a frequent
mechanism of HLA class I alterations in cancer. Cancers (Basel).
13:50462021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ciani Y, Fedrizzi T, Prandi D, Lorenzin F,
Locallo A, Gasperini P, Franceschini GM, Benelli M, Elemento O,
Fava LL, et al: Allele-specific genomic data elucidate the role of
somatic gain and copy-number neutral loss of heterozygosity in
cancer. Cell Syst. 13:183–193.e7. 2022. View Article : Google Scholar
|
|
26
|
Garavello W, Spreafico R, Somigliana E,
Gaini L, Pignataro L and Gaini RM: Prognostic influence of gender
in patients with oral tongue cancer. Otolaryngol Head Neck Surg.
138:768–771. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Roberts JC, Li G, Reitzel LR, Wei Q and
Sturgis EM: No evidence of sex-related survival disparities among
head and neck cancer patients receiving similar multidisciplinary
care: A matched-pair analysis. Clin Cancer Res. 16:5019–5027. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mazul AL, Naik AN, Zhan KY, Stepan KO, Old
MO, Kang SY, Nakken ER and Puram SV: Gender and race interact to
influence survival disparities in head and neck cancer. Oral Oncol.
112:1050932021. View Article : Google Scholar
|
|
29
|
Klein SL and Flanagan KL: Sex differences
in immune responses. Nat Rev Immunol. 16:626–638. 2016. View Article : Google Scholar
|
|
30
|
Castro A, Pyke RM, Zhang X, Thompson WK,
Day CP, Alexandrov LB, Zanetti M and Carter H: Strength of immune
selection in tumors varies with sex and age. Nat Commun.
11:41282020. View Article : Google Scholar : PubMed/NCBI
|
